Lung Cancer Trials Ask AI to find trials
UnknownEarly Phase 1NCT02568033
Official study title

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Study summary

This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy to treat stage II and III lung cancer that is not amendable to surgical resection.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPemetrexed and Carboplatin

Plus 4 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 31, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Early Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?The Cooper Health System

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Early Phase 1
Sponsor
The Cooper Health System
Interventions being studied
Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Docetaxel; Drug: Paclitaxel; Radiation: stereotactic radiosurgery
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
Treatment approach
Chemotherapy→Radiation therapy→Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Nonsmall cell lung cancer (NSCLC) (any histology)
  • unresectable stage II
  • Stage III
  • Tumor less than 8 cm
  • Karnofsky performance scale (KPS) of 50 or better
  • Three or fewer mediastinal or hilar lymph nodes
Reasons someone may not be able to joinExclusion criteria
  • Small cell lung cancer (SCLC)
  • Stage I and stage IV patients
  • Stage II patients eligible for surgical resection
  • Concurrent severe disease that the treating physician feels will interfere with therapy this can include significant cardiovascular or pulmonary disease.
  • KPS 40 or less (bed bound)
  • Tumor size greater than 8 cm
  • Inability to safely treat target lesions (at discretion of treating physician, this would most likely be secondary to not being able to place fiducial markers for tracking)
  • Four or more medisatinal or hilar lymph nodes

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • MD Anderson Cancer Center at CooperCamden, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 31, 2017. Always confirm current availability with the study team.

View original record ↗